Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Preventive Effect of Acetyl-L-carnitine on Oxaliplatin-induced Peripheral Neuropathy
NCT05601479Phase 2Unknown
- Sponsor
- Nanfang Hospital, Southern Medical University
- Start
- Nov 2022
- Primary completion
- Dec 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of acetyl-l-carnitine (2 arms), sponsored by Nanfang Hospital, Southern Medical University. Primary endpoint: Incidence rate of Oxaliplatin-induced Peripheral Neuropathy at 24 weeks. Status: unknown.
02
Drugs
acetyl-l-carnitine
Beyond the preview
Go deeper on NCT05601479.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05601479.